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Abstract 
Background and aims: Arterial hypertension is a major cause of death worldwide. For the most part, treatment for 
hypertension can be performed on an outpatient basis. However, some patients also require inpatient treatment, and 
the contributing factors for this remain unknown. Therefore, the primary objective of the present study was to deter‑
mine which patient characteristics are associated with inpatient treatment for arterial hypertension.
Methods: Here, we conducted a mono‑centric study of 103 hypertensive subjects, who were treated as inpatients in 
the Department of Nephrology and rheumatology of the university medical faculty of Göttingen. Therapies were not 
altered, and data collection was performed retrospectively. In addition to epidemiological information, the following 
data were recorded: patient symptoms, blood pressure (BP), anti‑hypertensive therapy, and concomitant diseases 
(e.g., renal and cardiovascular conditions).
Results: Approximately half (53 %) of all subjects treated on an inpatient basis displayed elevated BP 
(>140/90 mmHg), while the remaining 47 % of patients showed normotensive readings (<140/90 mmHg) following 
admission. Moreover, 34 % of patients could be classified as therapy refractory. The main reasons for hospital admis‑
sion were hypertension‑related symptoms, including shortness of breath, dizziness, and headache (69 %). These 
patients were multi‑morbid, with approximately 60 % displaying a secondary form of hypertension. Indeed, over half 
of the subjects showed renoparenchymatous forms of hypertension, and a large percentage of patients received 
hypertension‑inducing drugs (32 %). Moreover, a high proportion of inpatients were treated with reserve antihyper‑
tensives, with the most commonly used drug being Moxonidin.
Conclusion: The majority of hypertensive patients were hospitalized due to their clinical symptoms and not as a 
result of BP values alone. The high proportion of patients with secondary forms of hypertension or treated with BP‑
boosting medications was striking.
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Background
Arterial hypertension is a chronic medical condition 
in which blood pressure (BP) is elevated. It significantly 
increases the risk of heart disease, stroke, and renal insuf-
ficiency and is therefore a major cause of death globally 
[1, 2]. In spite of recent therapeutic advances, blood pres-
sure control remains suboptimal [3]. This is especially 
true for cases involving serious comorbid conditions 
(e.g., kidney disease) [4]. Therefore, achieving effective 
therapeutic intervention is fundamental, and ongoing 
investigation into the treatment of hypertensive patients 
is essential for ensuring successful clinical management.
Although hypertension is not usually accompa-
nied by symptoms, patients with severely elevated BP 
can experience effects (e.g., headaches, lightheaded-
ness, vertigo, and/or fainting episodes) [5]. However, it 
remains controversial whether such manifestations are 
directly linked to high BP or not [6–8]. Notably, symp-
toms can also be associated with secondary hyperten-
sion, which results from known underlying causes (e.g., 
kidney disease, endocrine abnormalities, or medica-
tions) [9, 10]. Thus, irrespective of the etiologic basis, 
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hypertension-associated symptoms can lead patients to 
pursue medical treatment.
For the most part, clinical management of hyperten-
sion is performed on an outpatient basis through life-
style modification and/or various antihypertensive drugs. 
However, hypertension can be treatment refractory [11]. 
In this regard, there are various classes of therapies that 
can be combined to optimize treatment [12], including 
reserve antihypertensive drugs (e.g., Moxonidin, Ebran-
til). Nevertheless, treating patients with resistant hyper-
tension can be complex, and its impact remains to be 
fully elucidated [13].
Recent studies have suggested that during hospitaliza-
tion uncontrolled BP is highly prevalent in hypertensive 
patients [14]. Thus, some individuals ultimately require 
inpatient treatment for elevated BP. However, the fac-
tors contributing to this and the benefit of such therapy 
are uncertain. Therefore, the objective of this study was 
to determine which patient characteristics are associ-




The present study was a mono-centric investigation 
involving 103 patients with arterial hypertension, who 
were treated as inpatients in the Department of Neph-
rology at the University Medical Faculty of Goettingen 
(Germany). Therapies were not altered during the study, 
which included all patients with arterial hypertension 
admitted to the Department of Nephrology in December 
2005. Moreover, this study was conducted in accordance 
with the Declaration of Helsinki. According to the guide-
lines of the ethics committee of the University Goettin-
gen, this study did not require ethics approval since (a) 
the data collection were performed retrospectively, (b) 
therapies were not altered and (c) individual patient data 
are not transferred outside the university. All patients in 
the study provided informed consent for participation, in 
line with the contract concerning medical treatment of 
the University Goettingen.
Data collection
Data were collected retrospectively by reviewing docu-
mentation made in patients’ charts. In addition to epi-
demiological data (i.e., age, gender, height, weight, 
body mass index [BMI]), the following information was 
recorded: patient symptoms (i.e., headaches, nosebleeds, 
dizziness, angina pectoris, nausea, blurred vision, night 
sweats, heart palpitations, shortness of breath); BP (fol-
lowing admission to the ward and upon discharge); anti-
hypertensive medications; and concomitant diseases 
(i.e., hyperthyroidism, pheochromocytoma, Cushing’s 
syndrome, Conn’s syndrome, renoparenchymatous 
hypertension, sleep apnea syndrome, renal artery steno-
sis). Also, we collected information with regard to renal 
function (i.e., creatinine, proteinuria [yes/no], level of 
CKD, dialysis [yes/no]) and cardiovascular disease/risk 
factors (i.e., myocardial infarction, coronary heart dis-
ease (CHD), diabetes mellitus, hyperlipidemia, smoking). 
ECGs were performed at hospital admission. The dataset 
of the current study is available from the corresponding 
author on reasonable request.
Statistical analysis
Continuous variables were summarized using descriptive 
statistics and are shown as means with standard devia-
tions, whereas categorical data are presented as the per-
centage (%) of subjects within each category.
Results
Here, we have conducted a mono-centric study of 103 
patients, who were treated as inpatients for arterial 
hypertension. Therapies were not altered, and data col-
lection was performed retrospectively. The primary 
objective of this investigation was to determine which 
patient characteristics are associated with the require-
ment for inpatient treatment for arterial hypertension.
Patient characteristics
The epidemiological characteristics of our study popula-
tion are presented in Table 1. These inpatients displayed 
a mean age of approximately 64 years and were approxi-
mately equally distributed with regard to sex. In addition, 
the average BMI for these subjects was 26.4, which indi-
cated an overall normal weight. Moreover, on average, 
they had experienced arterial hypertension for 12  years 
based on time of diagnosis.
BP values on the day of admission and discharge
We assessed the BP of our inpatient population after 
admission to the hospital ward and found surprisingly 
low values. In fact, almost half of all patients (47  %) 
exhibited BP values below 140/90 mmHg, with only 9 % 
of the subjects displaying grade 3 hypertension (Fig.  1). 
In order to determine whether inpatient care could lead 
Table 1 Patient characteristics
BMI body mass index
All patients (n = 103)
Age (years) 63.8 ± 14.8
Sex (% female) 49
BMI (kg/m2) 26.4 ± 4.8
Time of Diagnosis (years) 12.1 ± 8.4
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to improvements in these BP measurements, we also 
performed BP readings on the day of discharge. Indeed, 
74  % of all patients had BP levels below the limit of 
140/90  mmHg at the time of discharge, and there were 
no longer individuals presenting grade 3 hypertension 
(Fig. 1). Thus, subjects treated in the hospital for arterial 
hypertension collectively showed lower BP values than 
expected, and BP reduction could be effectively achieved 
through inpatient care.
Patient characterization based on reason for admission
Since high BP was the basis for hospitalization for only a 
few cases in our cohort, we next analyzed the overall rea-
sons for hospital admission in our patients. In this regard, 
we found that symptoms caused either directly or indi-
rectly by hypertension were the reason for admission in 
68.9 % of the patients. Notably, the most common symp-
tom that was reported was shortness of breath, which 
was followed by dizziness, headaches, and heart palpita-
tions (Fig. 2).
Proportion of patients with secondary hypertension
Among the patients hospitalized due to hypertension 
in the Department of Nephrology and Rheumatology, 
over 60 % were found to suffer from secondary forms of 
hypertension. In particular, more than half of the patients 
displayed renoparenchymatous hypertension. The over-
all frequency and causes of secondary hypertension in 
our patient population are presented in Fig.  3. Notably, 
secondary forms of hypertension that are not listed here 
(e.g., pheochromocytoma) were not observed in the pre-
sent study.
BP increasing medication
In addition to classical forms of secondary hyperten-
sion, we also collected data with regard to BP increasing 
medications. We found that 32 % of the subjects received 
drugs that could induce hypertension. These included 
mainly glucocorticoids, anti-inflammatory drugs (exclud-
ing aspirin, 100  mg), contraceptives, cyclosporins, and 
erythropoietins (Fig. 4).
Cardio‑renal co‑morbidities
We observed that patients admitted and treated for arte-
rial hypertension tended to be multi-morbid. Indeed, a 
large proportion of subjects displayed coronary heart dis-
ease (37 %) or renal insufficiency (56 %). Notably, 23 % of 
the patients had experienced a previous heart attack (13 %) 
or stroke (10 %). ECGs were performed in 85 patients at 
the time of admission (82.5 %). Of these, 79 (92.9 %) had 
a sinus rhythm, whereas 6 (7.1  %) had atrial fibrillation. 
The mean heart rate was 73.9 ±  15.7 bpm, with a maxi-
mum frequency of 118 bpm and a minimum frequency of 
50 bpm. Echocardiography was performed on 55 patients 
(53.4 %), with 28 (50.9 %) displaying left ventricular hyper-
trophy and 8 (14.5 %) a decreased ejection fraction (<55 %).
Fig. 1 Distribution of patients base pressure (BP) category on the day of admission and at discharge
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Medical treatment for hypertension
We also collected data with regard to antihypertensive 
medications on the day of admission and at discharge 
(Fig. 5). Notably, a total of 34 % of our patients met the 
definition of therapy-refractory hypertension, receiving 
three or more antihypertensive drugs (including a diu-
retic). We found that the most frequently prescribed 
drugs in our inpatient population were beta block-
ers, followed by thiazide diuretics. Moreover, 21  % of 
the patients received reserve antihypertensive therapy, 
Fig. 2 Distribution of hypertension‑related symptoms upon hospital admission
Fig. 3 Distribution of patients with secondary hypertension
Page 5 of 8Bramlage et al. BMC Res Notes  (2016) 9:480 
with the most commonly used drug being Moxonidin 
(12.6  %). This study did not examine patient adherence 
to the antihypertensive medication, but since 47.0  % of 
patients showed normotensive readings after admission 
(<140/90  mmHg), poor compliance can be assumed in 
many cases.
Discussion
In the present study, we have examined the characteris-
tics of individuals requiring inpatient treatment for arte-
rial hypertension. Strikingly, we found that approximately 
half of our patients displayed normotensive readings 
upon hospital admission. Despite this finding, hyperten-
sion-related symptoms constituted the principal reason 
for hospitalization. Moreover, almost one-third of these 
patients could be classified as therapy refractory, whereas 
approximately two-thirds displayed secondary forms of 
hypertension.
BP levels and the benefit of inpatient care
We observed lower than expected BP values on the 
day of admission. In fact, although the majority of our 
patients had presented with hypertension-related symp-
toms, only <10 % of them displayed grade 3 hypertension. 
However, since our BP measurements were documented 
after admission to the hospital ward, it is possible that 
emergency room BP values had been higher (i.e., rea-
son for hospital admission). Indeed, lower BP following 
hospital admission could result from reduced stress lev-
els or monitored intake of prescribed antihypertensive 
drugs (i.e., compliance) [15]. That being said, symptoms 
linked to hypertension have previously been reported to 
be unrelated to BP levels and instead linked with indirect 
factors, such as psychological issues (e.g., depression, 
anxiety), antihypertensive medications, and concomi-
tant diseases [6–8]. Therefore, it is possible that this phe-
nomenon may have also contributed to the lower than 
expected BP values in our admitted patients.
Inpatient treatment of our cohort led to improve-
ments in BP. Indeed, we observed an approximately 
50  % reduction in the number of patients with BP 
>140/90  mmHg at the time of discharge. This finding 
is interesting because it was previously shown that up 
to 77  % of inpatients treated for elevated BP remained 
hypertensive at the time of discharge and follow-up 
[14]. Nevertheless, our study was conducted within the 
Department of Nephrology and Rheumatology, which 
led to the inclusion of a high number of patients with 
renoparenchymatous hypertension. Thus, it is possi-
ble that the positive outcomes observed in the present 
study resulted from inpatient treatment of the large 
proportion of subjects displaying renal insufficiency and 
proteinuria (i.e., leading to reduced secondary hyper-
tension in these individuals). Nevertheless, it is also 
plausible that other factors associated with inpatient 
care (e.g., improved adherence to medications) could 
Fig. 4 Percentage of patients receiving hypertension‑inducing drugs
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also contribute to better short-term BP control in com-
parison to outpatient treatments [16, 17].
The expense associated with inpatient care is also an 
important consideration, as it has been suggested that 
outpatient care for hypertension is more cost effec-
tive [18]. Therefore, determining those patients that can 
benefit more from inpatient treatment could be highly 
advantageous from a cost perspective. In this regard, our 
findings represent an important step toward identifying 
such individuals. Taken together, our data preliminar-
ily demonstrate the efficacy of inpatient treatment for 
hypertension, and suggest the need for additional studies 
to establish the specific patient groups that will benefit 
most from this therapeutic option.
Secondary hypertension and hospitalization
It has been reported that approximately 5–10 % of adults 
with hypertension display an identifiable secondary 
cause [19]. However, in the present study we found that 
approximately two-thirds of our patient population pre-
sented with secondary hypertension. In this regard, the 
high proportion of patients with renoparenchymatous 
hypertension and/or treated with BP-boosting medica-
tions was striking. Therefore, it is possible that these 
characteristics are strongly associated with the need for 
inpatient treatment.
In this respect, the large proportion of individuals with 
renal insufficiency in our cohort might suggest that this 
comorbidity directly contributed to the need for hos-
pital admission, and thus the probability of inpatient 
treatment for hypertension. Nevertheless, it is known 
that secondary forms of hypertension, especially kidney 
disease, are often associated with therapeutic resistance 
[20], which also could require inpatient intervention. In 
this respect, the relationship between comorbidities and 
hypertension-inducing drugs cannot be overlooked with 
regard to augmenting the severity of resistant forms of 
hypertension and the need for hospitalization. Thus, our 
results obtained from this highly comorbid population 
highlight the complex interplay that may exist between 
comorbidities, BP-boosting drugs, and therapy refractory 
hypertension. However, further study will be required 
to determine which specific characteristics are most 
strongly correlated with the requirement for inpatient 
treatment. In particular, raising awareness with regard to 
the role of hypertension-inducing drugs may be impor-
tant for improving the management of these hypertensive 
patients. Indeed, our results suggest that more care may 
need to be taken when prescribing such drugs to high-
risk patients.
Regardless of the reason for admission, our data pre-
liminarily suggest that hospital supervision is especially 
beneficial for those with secondary forms of hyperten-
sion. Thus, inpatient care for these individuals may be 
necessary for efficient BP monitoring and control. Spe-
cific analysis of the different forms of secondary hyper-
tension should yield information with regard to their 
unique associations with inpatient treatment as well as 
the benefit that can be achieved through this type of care.
Resistant hypertension and anti‑hypertensive medications
The exact prevalence of resistant hypertension is 
unknown, but it has been reported to occur in 5–50  % 
of cases [21]. In the present study, almost one-third of 
Fig. 5 Distribution of patients based on the antihypertensive treatment on the day of admission and at discharge
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our patients was therapy refractory, suggesting that this 
characteristic may be linked to need for inpatient care. 
In addition, it was recently suggested that the preva-
lence of resistant hypertension is on the rise [22], which 
may mean that the establishment of specific guidelines 
for the effective management of hypertensive patients 
during hospitalization could be gaining importance. In 
this regard, the most effective combination therapies 
for effectively treating those with resistant hypertension 
remain to be determined [12]. Thus, identifying which 
antihypertensive drugs were most frequently adminis-
tered to our hospitalized patients was interesting from 
a medical perspective. We found that beta blockers and 
thiazide diuretics were the most common drugs used 
in our patients, and that Moxonidin was the most often 
prescribed reserve antihypertensive (followed by Ebran-
til). Although it is possible that the use of certain drugs 
could be linked with the need for inpatient treatment in 
hypertensive subjects, larger multi-center studies will 
be needed to provide evidence to link any specific treat-
ments to the requirement for inpatient care. Indeed, beta 
blockers and thiazide diuretics are commonly employed 
for the treatment of hypertension, and Moxonidin has 
shown a good safety and efficacy profile [23]. The rate of 
beta-blocker use was high at 49 %. This may due to the 
high proportion of patients with cardiac diseases, with 
37  % having coronary heart disease. Furthermore, the 
prevalence of therapy-resistant hypertension was 34  %, 
which corresponds to many patients being treated with 
more than three different anti-hypertensives, one of 
which is likely to have been a beta-blocker.
Study limitations
This study presented several limitations. In particular, 
our cohort of patients may not have been large enough 
to draw significant conclusions regarding patient charac-
teristics associated with inpatient treatment of hyperten-
sion. Nevertheless, the present study represents a first 
step in determining which patients require inpatient care 
as well as the value of this treatment option. In addition, 
the fact that our investigation was conducted specifically 
within the Department of Nephrology and Nephrology at 
a single institution may have created bias. Indeed, there 
was a large number of patients with renal insufficiency 
included in this study. Thus, future multi-center investiga-
tions involving different departments will be required to 
thoroughly assess the diverse patient characteristics that 
may be related to the need for inpatient therapy for hyper-
tension. Moreover, the lack of direct comparison between 
our cohort and outpatients is a limitation of our study. 
Indeed, in order to truly determine the characteristics 
that define patients treated on an inpatient basis, analysis 
of outpatients from the same institution will be required. 
In this regard, future studies aimed at assessing the ben-
efit of inpatient care as compared to outpatient treatment 
options will be required to fully assess specific character-
istics and therapeutic responses in hypertensive patients.
Conclusions
For the most part, patients with arterial hypertension 
were hospitalized due to their clinical symptoms and 
not as a result of BP values alone. The high proportion 
of patients with secondary forms of hypertension or 
treated with BP-boosting medications was striking. In 
addition, a large percentage of patients displayed resist-
ant hypertension. Thus, it is possible that these factors 
were associated with the need for inpatient treatment 
as a result of high BP. Taken together, these findings can 
contribute to improve the clinical management of hyper-
tensive patients. However, additional investigations will 
be needed to more thoroughly examine the relation-
ship between these characteristics and inpatient care as 
well as to verify that reductions in BP can be achieved 
through brief inpatient treatment.
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